Diagonal Bio AB Year-end Report 2023

"Looking back at 2023, I am proud to point out the significant steps we have made in our development, including the key achievements such as the CE-marking of LAMPlify® according to Low Voltage Directive (LVD) 2006/95/ EC. A highlight of our fourth quarter was the commencement of LAMPlify® commercialisation." says, Karin Wehlin, interim CEO Diagonal Bio AB.

Summary of Year-end Report 2023

2023-10-01 -- 2023-12-31 (October -- December)

** Net sales amounted to 23 KSEK (0 KSEK), capitalised development contributed with 405 KSEK (846 KSEK), while other operating income amounted to 7 KSEK (3 KSEK).

** Operating profit amounted to -2 462 KSEK (-3 938 KSEK).

** Operating profit per net weighted average share amounted to -0.06 SEK (-0.33 SEK).

** Cash flow during the fourth quarter amounted to -1 745 KSEK (2 817 KSEK).

** Cash and cash equivalents at the end of the period amounted to 2 972 KSEK (13 585 KSEK).

2023-01-01 -- 2023-12-31 (January -- December)

** Net sales amounted to 23 KSEK (203 KSEK), capitalised development contributed with 3 128 KSEK (3 503 KSEK) and other operating income amounted to 25 KSEK (28 KSEK).

** Operating profit amounted to -11 566 KSEK (-15 163 KSEK).

** Operating profit per net weighted average share amounted to -0.32 SEK (-1.7 SEK).

** Cash flow during the period amounted to -10 613 KSEK (-7 181 KSEK).

Significant Events during the Fourth Quarter of 2023

** On November 14, 2023, Diagonal Bio announced the initiation of a pilot study with Techtum Lab AB to identify genetic markers for herpes and influenza viruses in horses.

** On November 23, 2023, Diagonal Bio announced the appointment of board member Karin Wehlin as interim CEO, following a mutual agreement between the previous CEO and the board.

** On November 27, 2023, Diagonal Bio communicated that the Company had signed an agreement with Hörsholms Hästepraksis for a paid test period using the LAMPlify® system, marking Diagonal Bio's first customer revenue.

Significant Events after December 31, 2023

** On February 2, 2024, Diagonal Bio updated its financial situation, indicating efforts for a long-term financial solution to be announced in connection with the Year-end Report for 2023.

** On February 16, 2024, Diagonal Bio signed a distribution agreement with Techtum Lab AB.

For additional information about Diagonal Bio AB

Please contact:

Karin Wehlin, Interim CEO
Phone: [phone]
E-mail: [e-mail]

Kerstin Åkesson Jakobsson
Chair of the Board of Directors
Phone: [phone]
E-mail: [e-mail]

Certified Adviser

Svensk Kapitalmarknadsgranskning AB
E-mail: [e-mail]

Diagonal Bio is a Swedish Medtech company founded in 2020 with the vision to limit the spread of infectious diseases worldwide by creating an easy-to-use, cost-efficient, quick, and accurate platform technology based on Diagonal Bio's patented technology for detection of genetic markers.
At Diagonal Bio we are creating two separate product lines intended for different market segments: LAMPlify®️for the less regulated market segments; PANVIRAL®️ for the in-vitro diagnostic market segments.

www.diagonalbio.com

https://news.cision.com/diagonal-bio-ab/r/diagonal-bio-ab-year-end-report-2023,c3937751

https://mb.cision.com/Main/20405/3937751/2636565.pdf

(c) 2024 Cision. All rights reserved., source Press Releases - English